An important advance in treatment of COPD;improves quality of life for COPD patients
Chandigarh, August 13, 2015: Novartis Healthcare Private Limited(NHPL) announced todaythe launch of Sequadra Inhaler (indacaterol/glycopyrronium)110mcg/50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, indacaterolmaleate, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium bromide, a long-acting anticholinergic (LAMA), for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
“NHPLis working hard to optimize this important treatment to Indian patients in a timely way”, said Jawed Zia, Country President, Novartis India. “Once daily indacaterol/glycopyrroniumcombination reduces risk of annual rate of exacerbations by 31% compared to the current standard of care(twice-daily salmeterol+ fluticasone* combination) in patients with moderate-to-severe chronic obstructive pulmonary disease”.
According to Prof ClausVogelmeier, Professor of Medicine and Head of Pulmonary Division, Marburg University Hospital, Germany said, “Indacaterol/Glycopyrroniumcombination will offer these patients a much greater improvement in lung function and health related quality of life. This new therapy will change the management of COPD to the benefit of patients.”
This was reinforced by Dr Deepak Talwar, Pulmonologist, Head of Dept Pulmonary, Metro Hospital, Noida, who stated, “It is great news that patients in India will now have access to this important long-acting bronchodilator combination therapy as the product offers better efficacy and superior patient outcomes in terms of compliance and convenience against all available standard of care medications in our country.”
Indacaterol/glycopyrroniumcombination was developed for the treatment of COPD for patients in whom treatment with a single long acting bronchodilator (LABA or LAMA) does not provide an adequate control of respiratory symptoms.Indacaterol/glycopyrroniumcombination has demonstrated a statistically significant improvement in lung function at 2 hours post-dose at Week 26.
Date:
Thursday, August 13, 2015